Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
HAYWARD, Calif., Jan. 24, 2013
HAYWARD, Calif., Jan. 24, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. The Company expects to grant
the underwriters a 30-day option to purchase up to an additional 15% of the
shares of common stock offered in the public offering. The Company intends to
use the net proceeds from the offering for general corporate purposes. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering.
Jefferies & Company, Inc. is acting as sole book-running manager in the
offering and Leerink Swann LLC is acting as co-manager.
The securities described above are being offered by the Company pursuant to a
shelf registration statement previously filed with, and declared effective by,
the Securities and Exchange Commission (the "SEC"). A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be filed
with the SEC and will be available on the SEC's website at
http://www.sec.gov. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering, when available, may be
obtained from Jefferies & Company, Inc., Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or
by telephone at 877-547-6340, or by email at
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of any such state or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its proposed offering, including its intention to offer and sell shares, its
intention to grant the underwriters an option to purchase additional shares
and its intended use of proceeds from the offering. Such statements are based
on the Company's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual results to
differ materially, including but not limited to the risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the proposed offering, as well as those set forth in the
Company's public filings with the SEC, including the Company's Annual Report
on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form
10-Q for the quarter ended September 30, 2012. The Company disclaims any
intent or obligation to update any forward-looking statements, whether because
of new information, future events or otherwise, except as required by
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., email@example.com or
SOURCE Anthera Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.